Tag: equity

-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population --

-- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo --

MONTREAL, July 07, 2025 (GLOBE NEWSWIRE) -- Boralex Inc. (TSX: BLX) (“Boralex” or the “Company”) announces the closing of an additional corporate financing of $250 million by way of an unsecured subordinated loan with a term of 8 years. The investment is made by La Caisse (formerly CDPQ), which is providing an amount of $200 million, to which is added a $50 million investment by a new partner, Fondaction.

Alm. Brand A/S share buy-back program

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Fortrea To Contact Him Directly To Discuss Their Options

VANCOUVER, British Columbia, July 04, 2025 (GLOBE NEWSWIRE) -- Jonathan Awde, of 1588-609 Granville Street, Vancouver, British Columbia, V7Y 1G5, today announced that on June 26, 2025, he acquired ownership of 3,150,000 Common Shares (“Common Shares”) in the capital of Carcetti Capital Corp. (“Carcetti”), a company with a head office at Suite 67 East 5^th Avenue, Vancouver, British Columbia, V5T 1G7, at a purchase price of CDN$0.125 per Common Share for an aggregate purchase price of CDN$393,750. Mr. Awde acquired ownership through a private placement transaction (the “Private Placement”) previously announced by Carcetti on April 25, 2025.

TORONTO, July 04, 2025 (GLOBE NEWSWIRE) -- AGF Management Limited reported total assets under management (AUM) and fee-earning assets¹ of $55.0 billion as at June 30, 2025.